Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients

AIDS

Volumn 18, Issue 14, 2004, Pages 1925-1931

  Sankatsing, Sanjay U C ^a,b,c   Jurriaans, Suzanne ^a   Van Swieten, Peter ^a   Van Leth, Frank ^b   Cornelissen, Marion ^a   Miedema, Frank ^a   Lange, Joep M A ^a,b   Schuitemaker, Hanneke ^a   Prins, Jan M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Intl Antiviral Ther Eval Center   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HIV reservoir; Mycophenolate mofetil; Ongoing replication

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ENZYME INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RNA, VIRAL;

EID: 3843110460     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409240-00008     Document Type: Article

References (30)

1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
2. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995, 1:1284-1290.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197.
6. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
7. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627-1632.
8. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
9. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
10. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000, 6:76-81.
11. van Rij R, van Praag R, Prins JM, Rientsma R, Jurriaans S, Lange JMA, et al. Persistence of viral HLA-DR - CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. Antivir Ther 2002, 7:37-41.
12. Chapuis AG, Paolo RG, D'Agostino C, Attinger A, Knabenhans C, Fleury S, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000, 6:762-768.
13. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action Immunopharmacology 2000, 47:85-118.
14. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993, 136:5-28.
15. Cohn RC, Mirkovich A, Dunlap B, Burton P, Chiu SH, Eugui E, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999, 68:411-418.
16. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995, 211:554-560.
17. Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999, 21:362-370.
18. Weverling CJ, Lange JM, Jurriaans S, Prins JM, Lukashov W, Notermans DW, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-F122.
19. van Praag RM, Wit FW, Jurriaans S, de Wolf F, Prins JM, Lange JM. Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 2002, 16:719-725.
20. Tindall B, Barker S, Donovan B, Barnes T, Roberts J, Kronenberg C, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988, 148:945-949.
21. Sankatsing SUC, Hoggard PG, Huitema ADR, Sparidans RW, Kewn S, Crommentuyn KML, et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and the intracellular nucleoside triphosphate pools. Clin Pharmacokinet 2004, in press
22. Sankatsing SU, Weverling GJ, Peeters M, Van't Klooster G, Gruzdev B, Rakhmanova A, et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003, 17:2623-2627.
23. Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, et al. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection. Antivir Ther 2003, 8:137-142.
24. Vrisekoop N, Sankatsing SUC, Jansen CA, Roos MTL, Otto SA, Schuitemaker H, et al. Normal immune reconstitution in acute and chronic HIV-1 infected patients with combined treatment of MMF and HAART. 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 657].
25. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
26. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6:82-85.
27. Fraser C, Ferguson NM, Anderson RM. Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc Natl Acad Sci USA 2001, 98:15167-15172.
28. Quemeneur L, Flacher M, Gerland LM, Ffrench M, Revillard JP, Bonnefoy-Berard N. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002, 169:2747-2755.
29. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002, 31:45-49.
30. Tambussi G, Rizzardi GP, Lazzarin A, Pantaleo G. Patterns of viral rebound and CD4 slopes in patients with primary HIV-1 infection with persistent undetectable viremia treated with supervised treatment interruption plus mycophenolate mofetil. 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 658].